Evidence map›Paper›PMID 40604239›Full record

ReviewNpj imaging2025

PET imaging of mycobacterial infection: transforming the pipeline for tuberculosis drug development.

Janke Kleynhans, Christiaan A Gouws, Thomas Ebenhan

Abstract readReview
In one paragraph

Review in Npj imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Janke KleynhansDepartment of Pharmaceutical and Pharmacological Sciences, Radiopharmaceutical Research, Katholieke Universiteit Leuven, Leuven, Belgium.
Christiaan A GouwsPreclinical Imaging Facility, Nuclear Medicine Research Infrastructure NPC, Pretoria, South Africa.
Thomas EbenhanPreclinical Imaging Facility, Nuclear Medicine Research Infrastructure NPC, Pretoria, South Africa. thomas.ebenhan@up.ac.za.

Funding

Fonds Wetenschappelijk Onderzoek - Vlaanderen 1226524N-7029University of Pretoria - Health Sciences UP-5963
6 · The paper itself

Abstract

Improved PET/CT radiopharmaceuticals can better visualize and monitor tuberculosis and enable real-time pharmacological drug profiling in vivo. PET/CT imaging can therefore be used to study in animal models the changes in tissue pathology in tuberculosis infection, such as mycobacterial latency, tuberculoma formation, lung cavitation or calcification, and extrapulmonary disease. This Perspective aims to critically evaluate the current and future contribution and role of PET imaging in anti-tuberculosis drug development.

Identifiers

PMID40604239
PMCPMC12441125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.